Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

Bio-Path Holdings, Inc.

ClinicalTrials.gov Identifier:

NCT01159028

First received: July 7, 2010

Last updated: July 18, 2016

Last verified: July 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	September 2016
Estimated Primary Completion Date:	September 2016 (Final data collection date for primary outcome measure)